EMT-6-hPD-L1
Strain Information
검증 데이터
Figure 1. Expression of human PD-L1 on EMT6-hPD-L1 cells was confirmed by flow cytometry.
EMT6-hPD-L1 cells and wild type EMT6 cells were stained with species-specific anti-PD-L1 antibodies. FACS analysis shows that human PD-L1 but not mouse PD-L1 was exclusively detectable on EMT6-hPD-L1 cells.
Figure 2. In vivo tumor growth curves in humanized EMT6-hPD-L1 syngeneic model.
BALB/c mice were subcutaneously injected 5×105 EMT6-hPD-L1 cells compared with wild type EMT6 cells as control. Tumor growth was monitored by measuring tumor size from day 7 after subcutaneous implantation.
Data shows that there were no significant differences between EMT6-hPD-L1 cells and wild type EMT6 cells in either tumorigenicity or tumor growth.
Figure 3. FACS analysis of PD-L1 expression on tumor cells derived from humanized EMT6-hPD-L1 syngeneic model with species-specific anti-PD-L1 antibodies.
Data shows that neither human PD-L1 nor mouse PD-L1 was detectable in EMT6-hPD-L1 knock-in tumor. This EMT6-hPD-L1 cell line can only be used for in vitro validation not for in vivo experiments.
Related Strain(s)
당신은 또한 좋아할 수 있습니다
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
조회At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
조회